Pediatric Hematology/Oncology

Liver and Pancreas Tumors

Questions discussed in this category

In a patient with recurrent fibrolamellar HCC a year after upfront resection (previously refused adjuvant therapy) with a solitary abdominal mass, would you offer neoadjuvant therapy to assess response?

Or offer resection followed by adjuvant therapy?

2 Answers available

What are best practices for oncologists during the national platinum shortage?

Please specify how your institution is allocating resources now or will be soon.

13 Answers available

How do you approach relapsed hepatocellular malignant neoplasm NOS after transplant in pediatric or AYA patients?

2 Answers available

What would be your next line of treatment for disease control in a pediatric patient with metastatic hepatocellular carcinoma in partial response after multiple therapies?

The patient already received PLADO+sorafenib, Y90, and Atezolizumab/Bevacizumab complicated by recurrent episodes of bleeding from esophageal varices....

2 Answers available

How do you approach treatment of metastatic hepatocellular carcinoma in an adolescent?

Would you offer liver transplant in the setting of metastatic disease?

1 Answer available

How do you choose first or second-line systemic therapy for fibrolamellar hepatocellular carcinoma?

What are there most evidence-based options?

1 Answer available

Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?

2 Answers available

Papers discussed in this category

Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Oncologist, 2020 Mar 10

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

Semin Diagn Pathol, 2016 Dec 23

Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.

Journal of the National Cancer Institute, 2016-06

An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.

Pediatrics, 2014 Feb 02

Chemotherapy drug shortages in pediatric oncology: a consensus statement.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

The Journal of urology, 2018-12

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

N. Engl. J. Med.,

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Lancet Oncol., 2014 Feb 18

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Br J Cancer, 2014 Apr 15

Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.

Cancer, 2011-06-15

Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Eur J Cancer, 2017 Nov 28

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Lancet Oncol, 2021 Jan 18

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

J Clin Oncol, 2021 Apr 19

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

J Clin Oncol, 2003 Jul 01

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.

Pediatric Hematology/Oncology

Liver and Pancreas Tumors

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology